Intracellular thiol redox status regulates lymphangiogenesis and dictates corneal limbal graft survival

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 5, 2010, Pages 2450-2458

  Fukumoto, Akiko ^a   Maruyama, Kazuichi ^a   Walsh, Tony ^b   Kajiya, Kentaro ^c   Hamuro, Junji ^a   D'Amore, Patricia A ^b   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c Department of Shiseido Innovative Science Research and Development Center ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; E 1770; GLUTATHIONE DIETHYL ESTER; N,N DIACETYLCYSTINE DIMETHYL ESTER; NEUROPILIN 2; PODOPLANIN; THIOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 3; ACETYLCYSTEINE; DRUG DERIVATIVE; GLUTATHIONE; GLYCOPROTEIN; GP38 PROTEIN, MOUSE; MEMBRANE PROTEIN; N,N DIACETYLCYSTEINE; N,N-DIACETYLCYSTEINE; THIOL DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; XLKD1 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA LIMBUS TRANSPLANTATION; CORNEA TRANSPLANTATION; ENDOTHELIUM CELL; GRAFT SURVIVAL; INFLAMMATORY INFILTRATE; INTRACELLULAR SPACE; KERATITIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; DISEASE MODEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; OXIDATION REDUCTION REACTION; PERITONEUM MACROPHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETYLCYSTEINE; ANIMALS; BLOTTING, WESTERN; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, LYMPHATIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; GLYCOPROTEINS; GRAFT SURVIVAL; LIMBUS CORNEAE; LYMPHANGIOGENESIS; MACROPHAGES, PERITONEAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUROPILIN-2; OXIDATION-REDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFHYDRYL COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 77952500458     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4618     Document Type: Article

References (51)

1. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1:219-227.
2. Alitalo K. Growth factors controlling angiogenesis and lymphangiogenesis. Ugeskr Laeger. 2002;164:3170-3172.
3. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
4. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
5. Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamberassociated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999;31:1472-1475.
6. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
7. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115:2363-2372.
8. Kerjaschki D, Huttary N, Raab I, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006;12:230-234.
9. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest. 2005;115:2316-2319.
10. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113: 1040-1050.
11. Maruyama K, Asai J, Ii M, Thorne T, Losordo DW, D'Amore PA. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol. 2007;170:1178-1191.
12. Yamada J, Maruyama K, Sano Y, Kinoshita S, Murata Y, Hamuro J. Promotion of corneal allograft survival by the induction of oxidative macrophages. Invest Ophthalmol Vis Sci. 2004;45:448-454.
13. Yamada J, Hamuro J, Terai K, Kinoshita S. Major histocompatibility complex semi-matching improves murine corneal allograft survival under oxidative macrophage dominancy. Transplantation. 2007; 84:899-907.
14. Meister A. Mechanism and regulation of the glutamine-dependent carbamyl phosphate synthetase of Escherichia coli. Adv Enzymol Relat Areas Mol Biol. 1989;62:315-374.
15. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998;95:3071-3076.
16. Murata Y, Amao M, Yoneda J, Hamuro J. Intracellular thiol redox status of macrophages directs the Th1 skewing in thioredoxin transgenic mice during aging. Mol Immunol. 2002;38:747-757.
17. Murata Y, Yamashita A, Saito T, Sugamura K, Hamuro J. The conversion of redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in Janus family tyrosine kinase 3(-/-) and IL-2 receptor gamma(-/-) mice. Int Immunol. 2002;14:627-636.
18. Murata Y, Shimamura T, Hamuro J. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol. 2002;14:201-212.
19. Murata Y, Amao M, Hamuro J. Sequential conversion of the redox status of macrophages dictates the pathological progression of autoimmune diabetes. Eur J Immunol. 2003;33:1001-1011.
20. Murata Y, Ohteki T, Koyasu S, Hamuro J. IFN-gamma and proinflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol. 2002;32:2866-2873.
21. Vayalil PK, Iles KE, Choi J, Yi AK, Postlethwait EM, Liu RM. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1281-L1292.
22. Edirisinghe I, Yang SR, Yao H, et al. VEGFR-2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction. FASEB J. 2008;22: 2297-2310.
23. Mendoza MG, Robles HV, Romo E, Rios A, Escalante B. Nitric oxide-dependent neovascularization role in the lower extremity disease. Curr Pharm Des. 2007;13:3591-3596.
24. Thoft RA. Keratoepithelioplasty. Am J Ophthalmol. 1984;97:1-6.
25. Turgeon PW, Nauheim RC, Roat MI, Stopak SS, Thoft RA. Indications for keratoepithelioplasty. Arch Ophthalmol. 1990;108:233-236.
26. Kinoshita S, Ohashi Y, Ohji M, Manabe R. Long-term results of keratoepithelioplasty in Mooren's ulcer. Ophthalmology. 1991;98: 438-445.
27. Gazitt Y, Callander N, Freytes CO, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res. 2000;9:737-748.
28. Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer. 2000;83:887-891.
29. Tsai RJ, Sun TT, Tseng SC. Comparison of limbal and conjunctival autograft transplantation in corneal surface reconstruction in rabbits. Ophthalmology. 1990;97:446-455.
30. Kenyon KR. Limbal autograft transplantation for chemical and thermal burns. Dev Ophthalmol. 1989;18:53-58.
31. Matoba AY, Peeler JS, Niederkorn JY. T cell subsets in the immune rejection of murine heterotopic corneal allografts. Invest Ophthalmol Vis Sci. 1986;27:1244-1254.
32. Gillette TE, Chandler JW, Greiner JV. Langerhans cells of the ocular surface. Ophthalmology. 1982;89:700-711.
33. Niederkorn JY, Ross JR, He Y. Effect of donor Langerhans cells on corneal graft rejection. J Invest Dermatol. 1992;99:104S-106S.
34. Teunissen MB. Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. Histochem J. 1992;24:697-716.
35. Steinman RM. Dendritic cells. Transplantation. 1981;31:151-155.
36. De Jager MP, Linde SP, Nel CJ. [Does a correlation exist between positive wound cultures at the end of an operation and later wound and prosthetic sepsis?]. S Afr J Surg. 1992;30:178-181.
37. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997.
38. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103:11405-11410.
39. Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, et al. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci. 2002;43:2127-2135.
40. Chang L, Kaipainen A, Folkman J. Lymphangiogenesis new mechanisms. Ann N Y Acad Sci. 2002;979:111-119.
41. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol. 1998;160:1589-1597.
42. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003; 9:685-693.
43. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9:653-660.
44. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
45. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
46. Van der Veen G, Broersma L, Dijkstra CD, Van Rooijen N, Van Rij G, Van der Gaag R. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci. 1994;35:3505-3515.
47. Schledzewski K, Falkowski M, Moldenhauer G, et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1(+), F4/80(+), CD11b(+) macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol. 2006;209:67-77.
48. Slegers TP, Torres PF, Broersma L, van Rooijen N, van Rij G, van der Gaag R. Effect of macrophage depletion on immune effector mechanisms during corneal allograft rejection in rats. Invest Ophthalmol Vis Sci. 2000;41:2239-2247.
49. Maruyama K, Yamada J, Sano Y, Kinoshita S. Th2-biased immune system promotion of allogeneic corneal epithelial cell survival after orthotopic limbal transplantation. Invest Ophthalmol Vis Sci. 2003;44:4736-4741.
50. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5:74-80.
51. Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology. 1997;197:478-493.